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Abstract
Background: The aim of the study was to validate the Norwegian version of a self-administered
43-item questionnaire designed to assess quality of life in kidney transplant recipients, the End-Stage
Renal Disease Symptom Checklist – Transplantation Module (ESRD-SCL).
Methods: In total, 53 kidney transplant recipients from one university-affiliated hospital responded
to a questionnaire including the ESRD-SCL and the Short Form 36 (SF-36). We assessed internal
consistency reliability and test-retest reliability with 2 weeks between assessments. Construct
validity was assessed by correlations of the ESRD-SCL subscales with related and unrelated SF-36
scales, demographic, and clinical characteristics.
Results: Subscales of the ESRD-SCL showed good internal consistency reliability (Cronbach's =
0.72–0.81) and for the aggregate total scale α was 0.94. Test-retest reliability median 14 days apart
was excellent with intraclass coefficients ranging from 0.87 to 0.95. The pattern of correlations of
the ESRD-SCL scales with related and unrelated scales SF-36 scales and demographic and clinical
characteristics gave support to the construct validity of the ESRD-SCL.
Conclusion:  The Norwegian translation of the ESRD-SCL showed satisfactory internal
consistency reliability, test-retest reliability and construct validity, at the level of the original
German version.
Background
Kidney transplantation has a positive impact on survival
and morbidity of patients with end-stage renal disease.
Recently, there has been increasing attention to health-
related quality of life (HRQoL) as an important consider-
ation in evaluating the impact of kidney transplantation.
Kidney transplant recipients have better HRQoL than
transplant candidates maintained on hemodialysis [1,2],
and they experience an improvement of HRQoL in the
first months after transplantation [3,4].
The HRQoL in kidney transplantation can be evaluated
using generic tools, such as the Sickness Impact Profile
(SIP), the Nottingham Health Profile (NHP) or the Short
Form 36 (SF-36) [5]. Some disease-specific tools for eval-
uation of HRQoL in relationship to renal transplantation
have been developed, including the Kidney Transplant
Questionnaire [6], and the ESRD symptom checklist –
transplantation module (ESRD-SCL) questionnaire [7].
Also, the Kidney Disease-Quality of Life (KDQOL) ques-
tionnaire is commonly used [8-10], although it was not
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developed specifically for the evaluation of transplanta-
tion.
To conduct studies on HRQoL outcomes in kidney trans-
plant patients, it is necessary to adapt relevant question-
naires and tools to the appropriate language and assess
the psychometric properties of the questionnaires in rele-
vant populations. Based on content analysis and available
documentation, we identified the ESRD-SCL as a feasible
questionnaire for use in kidney transplantation, in partic-
ular to evaluate the effects of immunosuppressant medi-
cation [11].
The objective of the present study was to assess the relia-
bility and construct validity of a Norwegian version of the
ESRD-SCL in renal transplant recipients.
Methods
Subjects and study design
Kidney transplantation in Norway is centralized to Rik-
shospitalet University Hospital, Oslo; however, follow up
is decentralized and performed in several hospitals. In the
present study we aimed at including all consecutive kid-
ney transplant recipients in a population of about 65
recipients, who regularly visits the nephrology outpatient
clinic at Akershus University Hospital, irrespective of
medication and time since transplantation. During an
outpatient visit, the attending physician asked the patients
to participate and to give their written informed consent.
The participants received a package of self-administered
questionnaires to be filled in at home and mailed to the
study organizers. About 2 weeks after returning the ques-
tionnaires, the respondents received another identical
questionnaire by mail. We contacted eight of the partici-
pants by telephone, as a reminder after the first question-
naire administration. No reminders were used for the
retest.
We aimed at including 60 subjects in order to have data
from 50 subjects for analysis. In total 59 patients accepted
to participate; 53 returned the first questionnaire (90%),
and 48 the second questionnaire (81%). The Regional
committee for medical research ethics, Health Region East
(REK Øst) approved the study, and the participants signed
a declaration of informed consent.
Questionnaires
The package of questionnaires contained the following
instruments:
The ESRD symptom checklist – transplantation module (ESRD-SCL)
The ESRD-SCL was developed in Essen, Germany to assess
quality of life after renal transplantation, focusing on
transplantation-specific symptoms, side effects of immu-
nosuppressive therapy and psychological distress [7]. It is
available in German, English and Turkish versions [12].
The reliability, validity and responsiveness of this ques-
tionnaire have been assessed in a German population of
renal transplantation patients [7,13], and the question-
naire has been used to compare HRQoL of patients using
tacrolimus and ciclosporin-microemulsion [11].
The cultural and language adaptation of the ESRD-SCL
was done according to a recommended procedure [14].
Two Norwegian physicians fluent in German in parallel
translated the questionnaire into from German into Nor-
wegian. A group with the two translators and two other
members discussed the translations and agreed on a con-
sensus version. This consensus version then was back-
translated into German by a physician fluent in
Norwegian, but with German as his native language. The
backtranslated version was compared with the original
and discussed with the authors of the original version. The
questionnaires were considered conceptually and linguis-
tically equivalent. Before using the questionnaire, it was
pilot-tested in some patients with kidney failure and
found to be acceptable. The final Norwegian version of
the questionnaire is presented as an appendix [see Addi-
tional file 1].
Short Form 36 (SF-36)
The general health status questionnaire SF-36 intends to
assess aspects of health important to all patients. The SF-
36 is developed in the U.S., contains eight scales [15,16],
and two component summary scales, and has been exten-
sively validated; however with limited experience in kid-
ney transplant recipients. We used the Norwegian
standard SF-36 version 1.2 [17], assessing health status
during the past four weeks. The scales were scored from 0
(lowest level of functioning) to 100 (highest level of func-
tioning). The SF-36 has previously been used in Norwe-
gian kidney transplant recipients [18], and its
psychometric properties have been demonstrated in Nor-
wegian patients and scores for a normal population pre-
sented [17,19].
Demographic and clinical variables
At study entry, the attending physician recorded informa-
tion on the patients's renal disease, previous transplanta-
tions, time since transplantation, current medication, data
from the most recent physical examination including
height, weight, blood pressure, and comorbidity using
Charlson's comorbidity index, and some laboratory tests
(Hemoglobin, S-creatinine). In the self-administered
questionnaire, the patients reported some supplementary
demographic data, such as marital status, education, and
employment status.BMC Nephrology 2006, 7:17 http://www.biomedcentral.com/1471-2369/7/17
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Statistical analysis
Descriptive statistics are presented using the mean (SD),
median (range) or numbers (%). Internal consistency reli-
ability was assessed using Cronbach's α [20]. Test-retest
reliability was assessed over 2 weeks with an intraclass cor-
relation coefficient (ICC), using the average of raters in a
two-way mixed model ICC with absolute agreement defi-
nition.
Construct validity for the ESRD-SCL subscales was
assessed by comparing actual correlations with the SF-36
scales with apriori predicted correlations. Based on previ-
ous literature [7,21] and content analysis of the items of
the scales, we hypothesized that:
(1) The two ESRD-SCL dimensions Limited cognitive
capacity and Transplantation-associated psychological
distress would have the highest correlations with the SF-
36 scale Mental health.
(2) The correlation of the ESRD-SCL dimension Cardiac
and renal dysfunction would be highest with the SF-36
scale Physical functioning.
(3) The correlations between the two scales measuring
medication side effects and the SF-36 scales would be
weak.
(4) Associations with sociodemographic and clinical data
would be highest for employment, age, sex, time since
transplantation, and comorbidity, possibly in the range
0.08–0.30 roughly equivalent to an incremental R2 of
0.006–0.09 [7]. For comorbidity we used the Charlson
comorbidity index (range 2–8) [22]. We also investigated
the association with Hemoglobin, S-creatinine and
immunosuppressive regimen (tacrolimus/prednisolone
vs. ciclosporin/prednisolone), possibly being able to cap-
ture the characteristic side effects of ciclosporin of gum
and hair growth.
For correlations between the ESRD-SCL and SF-36 scales
we used Pearson's correlation coefficient. For correlations
of the ESRD-SCL scales with demographic and clinical
variable we used Spearman's rank correlations, because of
the ordinal nature of some of the data and the dichotomy
of some variables.
Finally, we assessed the capacity of the questionnaire sub-
scales subscales to discriminate between two known
groups, as defined by: (1) immunosuppressive regimen,
comparing tacrolimus/prednisolone (n = 9) with
ciclosporin/prednisolone (n = 39); (2) Age below/above
the sample median of 57.87 years; (3) comorbidity, using
Charlson comorbidity index above/below the median (≤2
vs >2). These or similar variables have been associated
with HRQoL following renal transplantation in previous
studies [7,21]. In this analysis we used analysis of vari-
ance/covariance, adjusting for age, sex and comorbidity
(Charlson comorbidity index ≤2 vs >2), where appropri-
ate.
Sample size for test-retest analysis was planned to about
50 patients, which is commonly used in the literature.
However, formal sample size calculation for test-retest
analysis or correlation analysis is rarely done and was not
carried out in the present study. We chose a 5% signifi-
cance level, using two-sided tests. The SPSS statistical soft-
ware version 12.0 (SPSS Inc., Chicago, IL) was used for all
analyses.
Results
The characteristics of the 59 respondents are shown in
Table 1. ESRD-SCL and SF-36 scores are shown in Table 2,
including the percentage of respondents giving lowest
(floor) and highest possible score (ceiling). The ESRD-
SCL scores did not concentrate at the ceiling for any sub-
scale. However, scores concentrated at the floor for the
Limited cognitive capacity, Side effects of corticosteroids,
and Increased growth of gum and hair subscales (Table 2).
For the SF-36 scales role – physical 30% of respondents
scored the lowest possible value (floor). There were
marked ceiling effects on the SF-36 scales role – physical
(40%), bodily pain (25%), social functioning (50%), and
role – emotional (67%) scales (Table 2).
The Cronbach's α was high for all dimensions of the
ESRD-SCL (α = 0.72–0.81), for the total scale (α = 0.94)
(Table 2), and for the scales of the SF-36 (α = 0.80–0.91).
In the test-retest the respondents (n = 48) completed
questionnaires median 14 days apart (interquartile range
9 to 20 days). In the test-retest, the intraclass correlation
coefficients for the different subscales of the ESRD-SCL
ranged 0.87 to 0.95, and for the SF-36 from 0.83 to 0.95.
In the assessment of construct validity, the hypothesized
associations between scales of the ESRDL-SCL generally
were among the highest, largely confirming the hypothe-
sis, although some of the other subscales also correlated
well (Table 3). The correlations of the two scales measur-
ing medication side effects with the SF-36 scales were
among the weakest pairwise correlations.
Among the demographic and clinical variables, employ-
ment showed the highest correlation with most of the
ESRDL-SCL subscales, although these correlations were all
weak and <0.40 (Table 4). Increased growth of gum and
hair, a typical side effect of ciclosporin, was moderately
associated with a ciclosporin-containing immunosup-
pressive regimen. With the above exceptions, associations
of the ESRDL-SCL subscales with demographic and clini-BMC Nephrology 2006, 7:17 http://www.biomedcentral.com/1471-2369/7/17
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cal variables were weak or close to nothing, as hypothe-
sized (Table 4).
Only the ESRD-SCL subscale Increased growth of gum
and hair discriminated between patients with two differ-
ent immunosuppressive regimens after adjustment for
age, sex, and comorbidity (Table 5). Only the two SF-36
scales Role – physical and Bodily pain discriminated
between patients below/above the median age in the mul-
tivariate model. On the ESRD-SCL subscale Side effects of
corticosteroids, younger patients tended indicate more
problems than those above the median age, although this
difference was statistically not significant (Table 5). The
SF-36 physical functioning scale was the only scale that
discriminated between patient groups according to Charl-
son comorbidity index ≤2 vs. >2 (p =< 0.001). The ESRD-
SCL subscales Limited physical capacity and Cardiac and
renal dysfunction showed differences that were almost
statistically significant (Table 5), however, we hypothe-
sized that these scales were associated with the Physical
functioning scale of the SF-36.
Discussion
In this cross-sectional study, the Norwegian version of the
ESRD-SCL demonstrated high internal consistency relia-
bility for all six subscales, in line with the original German
version (α = 0.76–0.85) [7]. Furthermore the test-retest
reliability over 2 weeks for all scales was excellent. Repro-
ducibility for the scales of this questionnaire has previ-
ously only been assessed over 1 year in stable patients [7].
It has been suggested that HRQoL instruments can be
used for comparisons at group level if reliability is above
0.70 [23]. All subscales of both the ESRD-SCL and the SF-
36 instruments had higher internal consistency reliability
than this. For use at the level of the individual patient, a
suggested minimum requirement for reliability is 0.90
while 0.95 is desirable [23] although perhaps too strin-
gent [24].
The pattern of correlations between the two instruments
largely confirmed hypothesized associations from litera-
ture review and item content analysis, hence supporting
convergent and discriminant validity of the ESRD-SCL
[25]. Furthermore, the associations of the ESRD-SCL sub-
scales with demographic and clinical variables were in
line with expectations. The patients accepted the ques-
tionnaire well, as demonstrated by the high completion
rates.
We found no difference in HRQoL between a tacrolimus-
based and a ciclosporin-based regimen using the SF-36,
and no systematic difference on the ESRD-SCL subscales
except the Increased growth of gum an hear subscale,
however our sample was small. Previous studies have
reported comparable effects on global HRQoL of the two
regimens, while Tacrolimus has tended to improved the
disease-specific HRQoL [11,26-30].
A previous study has reported lower scores, denoting less
side effects, on the Side effects of corticosteroids dimen-
sion of the ESRD-SCL and more suffering in the Limited
cognitive function and Increased growth of gum and hair
dimension among the elderly [7]. In the present study we
noted a statistically nonsignificant tendency to lower Side
effects of corticosteroids in the elderly, however there was
no indication of a difference according to age in the Lim-
ited cognitive dimension or Increased growth of gum and
hair dimension in the present study.
Table 1: Respondents' characteristics (n = 53), mean (SD) unless 
otherwise stated
Age, years 57.5 (13.2)
Female gender, number (%) 22 (42)
Married/cohabiting, number (%) 40 (76)
Education in years, number (%)
<10 17 (32)
10–12 22 (42)
>12 12 (26)
Body mass index, kg/m2 26.8 (5.8)
Systolic blood pressure, mmHg 131 (15)
Diastolic blood pressure, mmHg 78 (8)
S-creatinine, µmol/L 136 (74)
Hemoglobin, g/dL 13.6 (1.6)
Employment, number (%)
Full-time employed 18 (34)
Part-time employed 3 (6)
On sick-leave 4 (8)
Disability pension 15 (28)
Retired because of age 11 (21)
Other
Diagnosis, number (%)
Glomerulonephritis 19 (36)
Polycystic disease 14 (26)
Hypertensive renal disease 7 (13)
Diabetic nephropathy 7 (13)
Other 6 (12)
Type of transplantation, number (%)
Cadaveric 32 (60)
Living donor 21 (40)
Immunosuppression, number (%)
Ciclosporin A 40 (76)
Tacrolimus 10 (19)
Mycophenolate mofetil 20 (38)
Azathioprine 14 (26)
Prednisolone 51 (96)
Blood pressure medications, number (%)
0 18 (34)
19  ( 1 7 )
2 14 (26)
3+ 12 (23)
Charlson comorbidity index, median (range) 2 (2–8)
Time since transplantation, years (median (range)) 4.4 (0.4–29.1)BMC Nephrology 2006, 7:17 http://www.biomedcentral.com/1471-2369/7/17
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Table 3: Multitrait-multimethod correlation matrix. Pearson's correlation coefficients between subscales of the ESRD-SCL and SF-36
ESRD-SCL
n Limited 
physical 
capacity
Limited 
cognitive 
capacity
Cardiac and renal 
dysfunction
Side effects of 
corticosteroids
Increased growth 
of gum and hair
Transplantation-associated 
psychological distress
Total
SF-36
Physical functioning 53 -0.54** -0.38** -0.41** -0.38** -0.26 -0.38** -0.52**
Role – physical 53 -0.52** -0.43** -0.28* -0.04 -0.14 -0.27 -0.39**
Bodily pain 52 -0.74** -0.51** -0.52** -0.33* -0.31* -0.50** -0.65**
General health 51 -0.59** -0.41** -0.55** -0.32* -0.29* -0.38** -0.57**
Vitality 52 -0.69** -0.49** -0.44** -0.26 -0.39** -0.36** -0.60**
Social functioning 52 -0.58** -0.41** -0.28* -0.24 -0.16 -0.54** -0.50**
Role – emotional 51 -0.67** -0.44** -0.31* -0.24 -0.25 -0.52** -0.55**
Mental health 52 -0.54** -0.51** -0.15 -0.15 -0.02 -0.65** -0.46**
*<0.05 **<0.01
Table 2: Health-related quality of life scores and relaibility assessments
Scores Reliability
n Items Minimum Maximum Mean SD %min (floor) %max (ceiling) Internal consistency* Test-retest**
ESRD-SCL (range 0–4)
Limited physical capacity 53 10 0.10 2.50 0.74 0.54 0 0 0.80 0.95
Limited cognitive capacity 53 8 0 2.00 0.56 0.48 13 0 0.80 0.93
Cardiac and renal dysfunction 53 7 0 2.57 0.71 0.59 6 0 0.81 0.90
Side effects of corticosteroids 53 5 0 2.20 0.60 0.57 21 0 0.72 0.94
Increased growth of gum and hair 53 5 0 3.80 0.72 0.80 13 0 0.80 0.87
Transplantation-associated 
psychological distress
53 8 0 1.88 0.59 0.46 6 0 0.78 0.87
Total 53 43 0.07 2.07 0.65 0.43 0 0 0.94 0.95
SF-36 (range 0–100)
Physical functioning 53 10 20 100 73.1 24.5 0 13 0.91 0.87
Role – physical 53 5 0 100 54.7 43.3 30 40 0.89 0.88
Bodily pain 52 2 0 100 65.3 28.7 2 25 0.91 0.93
General health 51 5 0 100 57.5 26.0 2 2 0.85 0.95
Vitality 52 4 5 95 54.4 21.0 0 0 0.80 0.90
Social functioning 52 2 12.5 100 81 24.6 0 50 0.84 0.86
Role – emotional 51 4 0 100 78.4 34.5 0 67 0.80 0.83
Mental health 52 5 24 100 77.8 17.9 0 10 0.81 0.91
* Cronbach's α
** Intraclass correlation coefficient
Table 4: Spearman's rank correlation coefficients of subscales of the ESRD-SCL with demographic and clinical variables
n Limited 
physical 
capacity
Limited 
cognitive 
capacity
Cardiac and renal 
dysfunction
Side effects of 
corticosteroids
Increased growth 
of gum and hair
Transplantation-associated 
psychological distress
Total
Age (years) 53 0.22 0.18 0.18 -0.13 0.08 -0.06 0.09
Female (2) vs. male (1) 53 0.10 -0.04 0.25 0.34* -0.05 0.07 0.17
Employment (yes/no) 53 -0.38** -0.30* -0.23 -0.19 -0.37** -0.15 -0.34*
Time since transplantation (years) 53 0.19 -0.01 0.14 -0.17 0.14 -0.21 0.02
Charlson's comorbidity index 53 0.24 0.19 0.20 0.04 0.03 0.06 0.17
Hemoglobin (g/dL) 53 -0.14 -0.01 -0.29* -0.13 0.11 -0.18 -0.20
S-creatinine (umol/L) 53 0.16 0.11 0.20 -0.04 -0.06 0.13 0.15
CsA (2) vs. Tacrolimus (1) 48 0.08 0.06 0.06 -0.05 0.48** -0.11 0.08
No. of drugs for hypertension 53 0.15 0.08 0.15 0.03 -0.22 0.17 0.14
*<0.05 **<0.01BMC Nephrology 2006, 7:17 http://www.biomedcentral.com/1471-2369/7/17
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Some weaknesses of the study should be noted. This study
was a cross-sectional study in one hospital with a limited
sample size, and all patients were successful renal trans-
plant recipients.
The questionnaire contains items intended to assess side
effects of immunosuppressive medication. Hence, the
questionnaire can be a useful supplement to other ques-
tionnaires in studies of kidney transplantation, in particu-
lar in studies of variations in immunosuppressive
medication following transplantation.
Conclusion
In summary, we have demonstrated that the psychometric
properties of the Norwegian version of the ESRD-SCL
were satisfactory and in line with the German original.
Hence, the questionnaire can be recommended for use in
future studies. The present study was not designed to eval-
uate responsiveness, which should be assessed in a longi-
tudinal study.
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Table 5: Health-related quality of life scores according to immunosuppressive regimen, age below/above the median and comorbidity 
below/above the median
Ciclosporin* Age (years)** Charlson comorbidity index***
Tacrolimus and 
prednisolon
Ciclosporin and 
prednisolon
p ≤58.88 >58.88 p ≤2> 2 p
N 9 39 27 26 30 23
ESRD-SCL
Limited physical capacity 0.62 ± 0.18 0.82 ± 0.09 0.33 0.73 ± 0.11 0.81 ± 0.11 0.62 0.63 ± 0.10 0.91 ± 0.11 0.06
Limited cognitive capacity 0.45 ± 0.15 0.59 ± 0.08 0.43 0.57 ± 0.10 0.58 ± 0.10 0.93 0.46 ± 0.09 0.69 ± 0.10 0.10
Cardiac and renal dysfunction 0.72 ± 0.19 0.82 ± 0.08 0.21 0.73 ± 0.11 0.79 ± 0.11 0.71 0.62 ± 0.10 0.91 ± 0.12 0.07
Side effects of corticosteroids 0.67 ± 0.18 0.68 ± 0.09 0.20 0.71 ± 0.11 0.58 ± 0.11 0.16 0.53 ± 0.10 0.76 ± 0.12 0.16
Increased growth of gum and 
hair
0.19 ± 0.27 0.92 ± 0.09 0.02 0.74 ± 0.16 0.73 ± 0.16 0.98 0.61 ± 0.15 0.87 ± 0.17 0.26
Transplantation-associated 
psychological distress
0.67 ± 0.16 0.58 ± 0.08 0.60 0.66 ± 0.09 0.54 ± 0.09 0.38 0.56 ± 0.09 0.64 ± 0.10 0.56
Total 0.57 ± 0.14 0.73 ± 0.07 0.32 0.69 ± 0.08 0.68 ± 0.09 0.95 0.57 ± 0.08 0.80 ± 0.09 0.07
SF-36
Physical functioning 71.3 ± 6.5 73.8 ± 3.2 0.74 73.5 ± 4.3 68.1 ± 4.3 0.38 81.7 ± 3.8 59.9 ± 4.3 <0.001
Role – physical 70.6 ± 13.4 50.4 ± 6.6 0.18 70.3 ± 8.2 38.0 ± 8.3 0.009 55.6 ± 7.2 52.7 ± 8.2 0.80
Bodily pain 58.8 ± 9.4 65.2 ± 4.7 0.54 72.2 ± 5.6 55.3 ± 5.6 0.04 66.9 ± 5.0 61.0 ± 5.8 0.44
General health 49.6 ± 8.8 56.0 ± 4.5 0.52 61.0 ± 5.2 51.6 ± 5.2 0.21 60.8 ± 4.9 51.8 ± 5.5 0.23
Vitality 61.6 ± 7.3 51.0 ± 3.7 0.20 58.4 ± 4.2 48.7 ± 4.2 0.11 57.4 ± 3.9 49.8 ± 4.6 0.22
Social functioning 70.3 ± 8.1 81.3 ± 4.1 0.23 81.7 ± 4.9 77.9 ± 5.0 0.6 85.4 ± 4.5 74.3 ± 5.2 0.12
Role – emotional 71.1 ± 11.4 76.8 ± 5.7 0.66 85.4 ± 6.7 67.3 ± 7.1 0.08 81.4 ± 6.4 72.0 ± 7.3 0.35
Mental health 73.3 ± 6.2 76.7 ± 3.1 0.62 78.1 ± 3.6 76.4 ± 3.7 0.75 79.8 ± 3.4 74.7 ± 3.9 0.34
*adjusted for age, sex and comorbidity
** adjusted for sex and comorbidity
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